HOME >> BIOLOGY >> NEWS
Long-term ulcerative colitis study shows Remicade responders maintained improvement

WASHINGTON, DC, May 23, 2007 Findings presented today at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

The ACT extension trials were conducted in both the United States and Europe, under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the University Hospital Vienna, Austria. The data show that for patients who completed follow-up through week 56 of the extension trials, 92 percent reported mild or no disease activity, as measured by the Physician's Global Assessment (PGA). For patients followed through week 104, 97 percent reported mild or no disease activity.

At week 0 of the ACT extension trials, 76 percent of 229 responder patients enrolled had mild or no disease activity, as indicated by a PGA score of 0 or 1, and 41 percent had no disease activity (PGA score of 0). At week 56, 92 percent of those patients remaining in the extension trials (n=181) had mild or no disease activity, and 61 percent had no disease activity. At week 104, 97 percent of those patients remaining in the extension trials (n=97) had mild or no disease activity, and 75 percent had no disease activity.

"The data demonstrate the sustained efficacy of REMICADE for many patients with UC," said co-principle investigator Walter Reinisch, M.D., of the University Hospital Vienna, Austria. "Because UC is a chronic condition, many patients live with cycles of recurring flares. This can greatly hinder a person's social and professional life. The availability of therapies that quickly reduce symptoms and maintain response and remission long term is a significant benefit to patients."

Separate data also presented at DDW
'"/>

Contact: Melissa Katz
mkatz2@cntus.jnj.com
215-325-6875
Centocor, Inc.
23-May-2007


Page: 1 2 3

Related biology news :

1. Long-term marijuana smoking leads to respiratory complaints
2. Long-term cancer risk follows stem cell transplant recipients
3. Long-term ocean data confirm fishing puts species in double jeopardy
4. Long-term lead exposure linked to cognitive decline in older adults
5. Long-term changes in experience cause neurons to sprout new long-lasting connections
6. Long-term study shows brain function not impaired by tight diabetes control and hypoglycemia
7. Long-term ecological research should include studies on how social science interacts with ecosystems
8. Long-term memory controlled by molecular pathway at synapses
9. Scientists find gene target that may protect against Crohns disease and ulcerative colitis
10. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
11. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2020)... ... ... A team of researchers at the Icahn School of Medicine at Mount ... that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from ... The efforts are being led by Mone Zaidi, MD, PhD, MACP, Director of the ...
(Date:4/22/2020)... ... , ... RCH Solutions (RCH ), a global provider of Bio-IT computing ... Michael Wlodarczyk as Director of Sales and Business Development. Based out of RCH’s location ... strong presence across the Northeast. , “We continue to see increased demand for specialized ...
(Date:4/22/2020)... ... 21, 2020 , ... USDM Life Sciences , a ... a new managed service to improve quality management for regulated companies, Unify Compliance ... Life Sciences (USDM) – Unify Compliance Cloud is a suite of applications for ...
Breaking Biology News(10 mins):
(Date:5/9/2020)... ... 2020 , ... Worldwide Business with kathy ireland® will be ... 10, 2020 and Wednesday, May 13, 2020 at 8:00pm ET / PT – ... executives from Techolution and Bravado Pharmaceuticals . , As leaders ...
(Date:5/5/2020)... ... May 05, 2020 , ... ProductLife Group has marked the next ... the group after 13 years at Altran, where he was Group VP of Life ... and being a Pharmacist, Xavier was involved in his early career in the development ...
(Date:5/1/2020)... ... April 30, 2020 , ... The winners of Fast Company’s ... and concepts that are actively engaged and deeply committed to changing the world. ... out the top prize in the Experimental category. , The RASTRUM™ 3D Bioprinter ...
(Date:4/23/2020)... ... April 22, 2020 , ... Across the country, there is ... COVID-19. Virginia has only been receiving 50% to 7.7% of the personal protective ... Governor Northam told the Virginia Mercury, “While we appreciate what we’ve received from ...
Breaking Biology Technology:
Cached News: